Dr. Lata Chandi Thatai, MD

Dr. Thatai practices at Lahey Clinic in Burlington, Massachusetts, part of Beth Israel Lahey Health.

Dr. Thatai's NPI, 1447240858, was assigned on October 26, 2005. Dr. Thatai holds Massachusetts license 238463.

Dr. Thatai's primary practice is Lahey Clinic, at 41 & 45 Mall Road, Burlington, MA 01803 in Middlesex County. The practice phone is (781) 744-5100.

Dr. Thatai's primary practice is Lahey Clinic in Burlington, Massachusetts, part of Beth Israel Lahey Health. Dr. Thatai is also affiliated with Beth Israel Deaconess Medical Center. The medical group on file is Lahey Clinic. Dmand AI also links Dr. Thatai to 2 more hospitals, 1 home health agency and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Thatai practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Thatai's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Thatai's licenses on file in 2 states: Massachusetts and New Hampshire.

CMS data shows 957 Medicare services from Dr. Thatai across 8 procedure codes in 2024, for 408 Medicare patients. Medicare paid $69,631 for them.

CMS counts 408 Medicare patients who saw Dr. Thatai in 2024. The largest group is 75 to 84, with 173 patients. 75% of them have cancer, and 72% have high cholesterol. 9% are also on Medicaid. Their average risk score is 1.56, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Thatai's median patient age at 71, with 90% women.

In 2024, Dr. Thatai wrote 1,234 Medicare Part D claims for 301 patients. 93% of them were for generic drugs. CMS names the drug for 1,020 of them, across 21 drugs with 11 or more claims each, at $879,972 in total drug cost. In 2023, CMS named 1,075 claims across 22 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Dr. Thatai for performance year 2024, reported through an alternative payment model (APM). Dr. Thatai accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Thatai as offering telehealth.

Dmand AI links Dr. Thatai to 5 clinical trials, 4 of them phase 3 studies. 5 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Breast Neoplasms, Male. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 13 general payments to Dr. Thatai from 8 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 47% of the total. Clovis Oncology, Inc. paid the most, $338.